These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 6188871)

  • 1. Biological response modifiers.
    Oldham RK
    J Natl Cancer Inst; 1983 May; 70(5):789-96. PubMed ID: 6188871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological Response Modifiers Programme and cancer chemotherapy.
    Oldham RK
    Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologicals and biological response modifiers: fourth modality of cancer treatment.
    Oldham RK
    Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer therapy by biological response modifiers.
    Herberman RB
    Arzneimittelforschung; 1987 Feb; 37(2A):246-50. PubMed ID: 2436633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Present status of studies on the application of immunology to the diagnosis and therapy of cancer, with emphasis on monoclonal antibodies and cytokines].
    Tokunaga T
    Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 2):1358-66. PubMed ID: 3296954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beware the Medical-Industrial Complex.
    Stevens CW; Glatstein E
    Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NCI preclinical screen of biological response modifiers.
    Talmadge JE; Fidler IJ; Oldham RK
    Behring Inst Mitt; 1984 May; (74):189-94. PubMed ID: 6206841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of clinical trials with biological response modifiers.
    Herberman RB
    Cancer Treat Rep; 1985 Oct; 69(10):1161-4. PubMed ID: 2412692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer vaccines: preclinical studies and novel strategies.
    Palena C; Abrams SI; Schlom J; Hodge JW
    Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [BRM in the treatment of cancer].
    Takaku F
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-3):1597-602. PubMed ID: 2454612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer.
    Oldham RK; Thurman GB; Talmadge JE; Stevenson HC; Foon KA
    Cancer; 1984 Dec; 54(11 Suppl):2795-806. PubMed ID: 6437660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic therapy of melanoma with cytokines and lymphocytes.
    Bear HD; Hamad GG; Kostuchenko PJ
    Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologicals and biological response modifiers: new approaches to cancer treatment.
    Oldham RK
    Cancer Invest; 1985; 3(1):53-70. PubMed ID: 3918773
    [No Abstract]   [Full Text] [Related]  

  • 18. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotherapy: the fourth modality of cancer treatment.
    Oldham RK
    J Cell Physiol Suppl; 1986; 4():91-9. PubMed ID: 2427531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.